The surface chemistry and flocculation of coal

Imperial Users onl

İnternational prostate symptom score, prostate volum and uroflowmetry in patients with lower urinary tract symptoms

Bu çalışmada alt üriner sistem semptomlu (AÜSS) hastalarda üroflov parametrelerinin rolünü tanımlamak ve prostat boyutu arasındaki ilişkiyi değerlendirmek amaçlandı. AÜSS'lu 90 hasta değerlendirildi. Maksimum akım hızı (Q max), ortalama akım hızı (Qave), maksimum akıma ulaşma zamanı (T to max), total işeme zamanı (V time), akım zamanı (T flow) ve işenen idrar miktarı (V vol) değerlendirildi. Uluslararası prostat semptom skoru (I-PSS) ile maksimum akım hızı (Q max), ortalama akım hızı (Q ave), işenen idrar miktarı (V vol) arasında ilişki vardı. Uluslararası prostat semptom skoru (I-PSS) yüksek olanlarda bu üç parametre düşüktü. Maksimum akım hızına (Q max) prostat boyutunun etkisi anlamlıydı. Prostat boyutu arttıkça maksimum akım hızı (Q max) azalıyordu. Sonuçta prostat boyutu ile maksimum akım hızı (Q max), ortalama akım hızı (Q ave), işenen idrar miktarı (V vol) arasında, uluslararası prostat semptom skoru (IPSS) ile maksimum akım hızı (Q max) arasında belirgin bir ilişki vardı. Bu sonucun klinik olarak tanımlanan Benin Prostat Hiperplazisinin (BPH) objektif kriterlere göre ortaya konmasına yardımcı olacağını düşünmekteyiz.This study was designed to justify the role of various uroflow parameters in patients with low urinary tract symptoms (LUTS) and to determine the relationship between uroflow parameters and prostate size. We evaluated 90 consecutive patients with LUTS. The international prostate symptom score (I-PSS) was used to evaluate subjective symptomatology. Maximal uroflow rate (Q max), average flow rate (Q ave), time from onset of flow to maximal flow, total voiding time, flow time and voided urine volume were evaluated. A relationship was found among international prostate symptom score (I-PSS) and maximal uroflow rate (Q max), average flow rate (Q ave) and voided volume as well. These three parameters decreased as the international prostate symptom score (I-PSS) increased. The influence of prostatic volume on maximal uroflow rate (Q max) was significant. Prostatic volume increased as maximal uroflow rate (Q max) decreased. As a conclusion, there is a great relationship among prostatic volume and maximal uroflow rate (Q max), Average flow rate (Q ave) and voided volume, among international prostate symptom score (I-PSS) and maximal uroflow rate (Q max). This result may help determine the clinical definition of BPH

Renal cell carcinoma: new prognostic factors?

Purpose of revie

UROLOGICAL RESEARCH

Several urinary markers for transitional cell carcinoma have been investigated, including urine cytology, bladder tumor antigen, autocrine motility factor receptor and fibrin degradation products. Unfortunately, they have poor overall sensitivity. The United States Food and Drug Administration have recently approved nuclear matrix protein (NMP 22) for the detection of occult or rapidly recurring disease after transurethral resection of bladder tumor. The objective of the current study was to assess the sensitivity of NMP 22 for the detection of bladder carcinoma, as well as to correlate the NMP 22 values with multiplicity of tumor, tumor size, configuration, stage and grade respectively. A total of 78 patients (38 with bladder cancer) provided a urine sample which was divided into appropriate aliquots for each of urine cytology and NMP 22. Comparative results demonstrate a clear superiority of NMP 22 in bladder cancer detection (52.6% vs 31.6% sensitivity), while specificity was in favor of urine cytology (100% vs 82.5%). For superficial tumors, sensitivity was 78.5% for NMP 22 and 41.6% for cytology and for invasive cancers, sensitivity was 90% for NMP 22 and 60% for cytology. Urinary NMP 22 levels were significantly correlated with tumor grade and were significantly higher in large tumors than small tumors. NMP 22 test results showed sufficient sensitivity in comparison with urine cytology for the detection of transitional cell carcinoma. However, we do not think that it is a useful tool as a substitute for endoscopic examination for the detection and surveillance in bladder cancer

WORLD JOURNAL OF UROLOGY

The relationship between serum lipid levels and measures of benign prostatic hyperplasia was investigated. The study was community based. All the participants had undergone a urological investigation which included International Prostate Symptom Score (I-PSS) and Quality of Life Score (QoL), serum lipid concentrations and determination of prostate volume with transrectal ultrasonography. Body mass index was calculated with the formula of weight (kg)/surface area (m(2)) respectively. Men were considered obese if their body mass index was over 25 kg/m(2). BPH was defined by prostate volume greater than 20 ml and I-PSS greater than seven. Comparisons of serum lipid levels between men with BPH and without BPH were done. There was no correlation for serum lipid levels with either mean I-PSS and QoL scores. However, triglyceride and cholesterol levels were the lowest in severe symptomatic men than men with low symptoms. Using clinical definition of BPH that prostate volume was greater than 20 ml and I-PSS was greater than seven, men with BPH had not significantly different serum lipid levels from men without BPH. Our population-based data reflect that there was no relationship between serum lipid levels and certain physiological measures of lower urinary tract symptoms and clinical benign prostatic hyperplasia

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION

Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit. [J Chin Med Assoc 2010;73(5):262-264